Hong Kong IT Stock News

Weimob stock closed at HK$1.11 on Wednesday, capping a weak run with the share price down about 10% over the past week and about 15% over three months. The headline from these H1 2026 results is not a revenue miss or surprise beat. It is the strain of ongoing losses sitting on top of a valuation that already prices the company at about 2.3x sales, above the Hong Kong software peer group. For short term traders that combination stings. For long term investors the key question is whether the...

Shanghai Seer Intelligent Technology’s stock has barely budged over the past week, yet the earnings story is anything but flat. The company is still loss making, with a basic H1 2026 loss per share of ¥0.38, but revenue reached ¥264.4m and it continues to carry a premium P/S of 11.3x against a far lower Hong Kong machinery industry average. The market’s calm reaction contrasts with a report that sharpens a key question for you: is this high revenue growth story with ongoing losses worth such...

Qinqin Foodstuffs Group (Cayman) came into this earnings day with a stock that has drifted, down about 13% over the past week and roughly 14% over three months, despite trading near a discounted cash flow fair value estimate far above the current HK$0.90 price. The headline from H1 2026 is simple: the company stayed modestly profitable, with basic earnings per share of CNY 0.007 and net income of CNY 4.937 million, yet the trailing twelve month picture still shows a loss and an uncovered...

Xiaomi stock closed at HK$27.44 after the Q2 2026 print, leaving investors to weigh a flat near term share price against earnings that were all about profit quality. The headline was simple: revenue reached RMB 108.9b while net income excluding extra items came in at RMB 9.5b. However, the real story sat in a group gross margin close to 19.8%. For a consumer electronics and smart devices company that lives or dies on hardware economics, that margin outcome will matter more to your view on...

Tsaker New Energy Tech stock has quietly climbed 15.8% over the past month, yet today’s headline is not the share price. The real story is a sharp swing back into profit in the chemicals business. Half year 2026 basic earnings per share landed at C¥0.10 on revenue of C¥1,413.1m, a very different picture from the loss reported in the second half of 2025. For a company that carries a five year record of steep earnings decline and a P/E below sector averages, this latest profitable half raises a...

Tingyi (Cayman Islands) Holding (SEHK:322) reported higher sales and net income for the half year to June 30, 2026. This points to improved operating performance and gives investors fresh earnings data to assess. See our latest analysis for Tingyi (Cayman Islands) Holding. The latest results from Tingyi (Cayman Islands) Holding come as momentum in the stock has been building, with an 18.1% 1 month share price return and a 35.9% 1 year total shareholder return, suggesting investors are...

Amidst a backdrop of easing inflation concerns and mixed performances across major indices, global markets continue to navigate a complex landscape. For investors seeking unique opportunities, penny stocks—often representing smaller or newer companies—remain an intriguing area of exploration. Despite being considered a throwback term, these stocks can offer growth potential at lower price points when paired with solid financials and strong fundamentals.

Everest Medicines Limited has released its interim results for the half year ended June 30, 2026, reporting CNY 1,147.84 million in sales versus CNY 446.12 million a year earlier and a sharply reduced net loss of CNY 5.94 million compared with CNY 249.79 million. This swing toward near break-even, with basic and diluted loss per share narrowing from CNY 0.77 to CNY 0.02, suggests operating progress that could meaningfully influence how investors view the company’s path to...

CSPC Pharmaceutical Group recently reported three developments: U.S. FDA approval to begin clinical trials for its mpox mRNA vaccine, a US$10,000,000 milestone payment from AstraZeneca tied to their small-molecule collaboration, and a joint venture with AstraZeneca to build a biologics manufacturing facility in Shijiazhuang, China. Together, these moves expand CSPC’s innovative vaccine and drug pipeline while pushing its manufacturing and quality systems further onto the global stage. We’ll...

Unitree Robotics’ huge Shanghai IPO debut has thrown a spotlight on Chinese robotics and automation stocks, as investors look for ways to tap into this wave of excitement and policy support. That surge in attention can quickly reshape how related companies are viewed and valued, which creates both opportunity and risk. This article walks through 3 stocks exposed to the same news, to help you decide which deserve a closer look. The 3 stocks below are just a small sample of what this Chinese...

Half year earnings put Uni-President China Holdings in focus Uni-President China Holdings (SEHK:220) has come into focus after reporting half year earnings to June 30, 2026, with sales of CNY 17,320.97 million and net income of CNY 1,402.35 million. See our latest analysis for Uni-President China Holdings. At a share price of HK$7.905, Uni-President China Holdings has seen a 3.88% 1 month share price return and a 66.55% 3 year total shareholder return, suggesting long term momentum despite a...

We feel now is a pretty good time to analyse Minieye Technology Co., Ltd's ( HKG:2431 ) business as it appears the...

Chongqing Machinery & Electric Co., Ltd. ( HKG:2722 ), is not the largest company out there, but it received a lot of...

The recent price decline of 12% in Huicheng International Holdings Limited's ( HKG:1146 ) stock may have disappointed...

Insiders who bought CN¥5.40m worth of Regal Partners Holdings Limited's ( HKG:1575 ) stock at an average buy price of...

While it’s been a great week for Crosstec Group Holdings Limited ( HKG:3893 ) shareholders after stock gained 25%, they...

It's been a pretty great week for Genscript Biotech Corporation ( HKG:1548 ) shareholders, with its shares surging 15...

As the Asian markets navigate a landscape marked by easing inflationary pressures and shifting economic policies, small-cap stocks have emerged as a focal point for investors seeking growth opportunities. In this dynamic environment, identifying undervalued small-cap companies with notable insider activity can provide insights into potential investment prospects.

Amidst a backdrop of mixed economic signals and geopolitical uncertainties, Asian markets have shown resilience with some indices experiencing notable gains. In this context, identifying undervalued stocks becomes crucial as investors seek opportunities to capitalize on potential discounts in the market.

CARsgen Therapeutics Holdings (SEHK:2171) has drawn fresh attention after its allogeneic CAR T-cell candidate CT0596 received IND clearance from China’s National Medical Products Administration for relapsed or refractory multiple myeloma. See our latest analysis for CARsgen Therapeutics Holdings. The CT0596 IND clearance arrives as CARsgen Therapeutics Holdings trades at HK$14.7, with a 1 day share price return of 2.15% and a 90 day share price return down 16.62%. The 1 year total shareholder...

The market has been lukewarm on Billion Industrial Holdings, with the stock flat over the past week and down about 14% over the past month. Yet the latest half year numbers land with far more punch than that price action suggests. H1 2026 revenue reached ¥12,712.2m and net income came in at ¥985.3m, which translates to basic earnings per share of ¥0.47. For a stock trading on a P/E of 7.8x, the key headline is simple: profitability looks stronger on recent figures than the share price...

Innovent Biologics (SEHK:1801) caught investor attention after reporting product revenue of over CN¥4.3b for Q2 2026 and more than CN¥8.2b for the first half, supported by its dual engine growth strategy. See our latest analysis for Innovent Biologics. Those revenue headlines have arrived alongside firm share price momentum, with Innovent Biologics delivering a 30 day share price return of 8.66% and a 90 day share price return of 21.73%, while the three year total shareholder return of...

Cowell e Holdings closed at HK$24.8 after the earnings release, with the stock coming in on the back of a mixed few months that included a recent 7 day gain and a weaker 90 day stretch. The headline from this set of numbers is not revenue size but profitability quality. Net income from continuing operations over the last twelve months reached US$217.2m and basic earnings per share for that period came in at US$0.254924. The market now has to decide if today’s move fairly reflects that...

China Industrial Securities International Financial Group closed today at HK$0.63, with the stock barely budging over the past month. The calm share price masks a sharp earnings step up. First half 2026 net income reached HK$137.7 million, with basic earnings per share at HK$0.0344. The trailing twelve month net profit margin sits at 21.3%. For a capital markets firm, that level of profitability is the key development. Short term traders may focus on the flat chart, while long term investors...